About
Targeted protein degradation has emerged as one of the most exciting frontiers in drug discovery, offering the potential to eliminate disease-causing proteins that have long evaded conventional therapeutic approaches. Molecular glue degraders—small molecules that redirect the ubiquitin-proteasome system to selectively degrade specific target proteins—represent a particularly promising avenue within this field. However, identifying such compounds requires screening large chemical libraries with high precision and reproducibility.
In this webinar, our collaborator at LUMS will present a large-scale drug screen of over ~6,000 compounds to identify novel molecular glue degraders targeting GSPTI, a translation termination factor critical to cancer cell survival. We will discuss how the Formulatrix Tempest® high-throughput dispenser and F.A.S.T.™ liquid handler enabled this screen, delivering the throughput, accuracy, and reproducibility required to generate reliable data at scale while keeping reagent consumption in check.
Tempest - Liquid Dispenser
F.A.S.T. - Liquid Handler
Join us to learn how laboratory automation is accelerating drug discovery workflows and how the right instrumentation can make large-scale screening both scientifically rigorous and operationally efficient.
When
July 30th 2026
Session 1
10:00 AM - 10:30 AM CEST
(09:00 AM - 09:30 AM BST)
Session 2
01:00 PM - 01:30 PM ET
(10:00 AM - 10:30 AM PT)
What You Will Learn
- How the Tempest high-throughput dispenser and F.A.S.T. liquid handler deliver the precision needed for reliable data at scale
- How automated liquid handling helps control reagent consumption across a large compound library
- How the right instrumentation choices can make large-scale screening both scientifically rigorous and operationally efficient
Who Should Attend
- Drug discovery scientists, medicinal chemists, and biologists working in targeted protein degradation research
- Screening and automation specialists in pharma, biotech, or academic settings
- Lab managers and principal investigators evaluating high-throughput liquid handling solutions for compound library screening
About the Speaker:
Dr. Amir Faisal received his PhD in Cell Biology from the Friedrich Miescher Institute for Biomedical Research, University of Basel, Switzerland, in 2004. He trained at the London Research Institute and the Institute of Cancer Research, UK, where he advanced several drug discovery programs, including one that entered Phase I clinical trials. Since 2014, he has been establishing and leading the Cancer Therapeutics Laboratory at LUMS, with a focus on translational research and drug discovery.